QNTM Multiplikator forward rega marang pendapatan Quantum BioPharma Limited
The creation of a diversified biopharmaceutical environment with a closed-loop production cycle has catalyzed current transformations for Quantum BioPharma Ltd (QNTM). The forward P/S trajectory clearly visualizes these processes, with serving as the current metric level. Consequently, Quantum BioPharma Ltd (QNTM) is developing neuroprotective formulas and analgesics while simultaneously conducting an internal asset review to reduce costs and align the profitability of its niche segments.
Rincian analitis perusahaan Quantum BioPharma Corp (QNTM)
- rega pasar lan target rega analis:
- data kapitalisasi pasar:
- rincian valuasi buku bisnis:
- indikator beban kredit lan likuiditas emiten:
Rasio Total Utang marang Ekuitas Quantum BioPharma Ltd|QNTM - Rasio silihan jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Quantum BioPharma Ltd|QNTM - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Quantum BioPharma Corp|QNTM - Kewajiban jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Quantum BioPharma|Rasio cepet quantumbiopharma.com
- rincian asil keuangan lan kelipatan valuasi:
QNTM - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Quantum BioPharma Ltd|QNTM - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Quantum BioPharma Limited|QNTM - Rega marang bathi kanthi panyesuaian wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Quantum BioPharma Corp|QNTM - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Bathi resik saben saham (EPS TTM) Quantum BioPharma|QNTM - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan quantumbiopharma.com|QNTM - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Quantum BioPharma Ltd
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:QNTM (Quantum BioPharma)
The integration of its own R&D and production facilities along with B2B distribution into the Quantum BioPharma Ltd (QNTM) ecosystem directly impacts expected revenue dynamics. By analyzing the company's forward P/S ratio, an investor compares market capitalization with projected sales volume, which allows for the determination of the asset's overvaluation and the balancing of capital risks against the long-term growth potential of the biopharmaceutical business.
Pesaing Quantum BioPharma Ltd (QNTM)
Rasio rega marang prakiraan pendapatan Haleon HLN|Prakiraan rega marang pendapatan Kenvue Inc|VRNA: Multiplikator forward rega marang pendapatan|MENS - Multiplikator Forward P/S|LGND: Multiplikator Forward P/S|amneal.com (AMRX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Perrigo|Kapitalisasi marang prakiraan pendapatan ALVO (Alvotech S.A.)|Multiplikator forward rega marang pendapatan LQDA (Liquidia Technologies)|Rasio rega marang pendapatan sing dikarepake GLPG|ANI Pharmaceuticals - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S mannkindcorp.com MNKD|AMPH - Rasio rega marang prakiraan pendapatan|Pacira Pharmaceuticals (PCRX) - Multiplikator forward rega marang pendapatan|SPRY (ARS Pharma) - Multiplikator forward rega marang pendapatan|Theravance Corp - Rega forward marang dodolan|AQST (Aquestive Therapeutics) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan SCPH|Multiplikator Forward P/S TECX|Rasio kapitalisasi marang dodolan sing dikarepake Tonix Pharma|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|Eupraxia Pharmaceuticals, Inc. (EPRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|BHST - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan EXOZ|ORMP: Multiplikator Forward P/S|Entera Bio - Rega forward marang dodolan|HYFT (MindWalk) - Multiplikator Forward P/S|Multiplikator Forward P/S ABVC BioPharma, Inc|Rasio rega marang prakiraan pendapatan Cumberland Pharmaceuticals (CPIX)|FGEN (fibrogen.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Telomir Pharmaceuticals, Inc. TELO|RANI - Multiplikator forward rega marang pendapatan|Synergy CHC Corporation - Multiplikator Forward P/S|RLYB - Multiplikator Forward P/S|LEXX (lexariabioscience.com) - Multiplikator forward rega marang pendapatan|pulmatrix.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Pheton Holdings Limited|Rasio rega marang prakiraan pendapatan APM|Multiplikator forward rega marang pendapatan LYRA (Lyra Therapeutics, Inc)|Rasio rega marang pendapatan sing dikarepake IBO|Multiplikator Forward P/S TNFA (TNF Pharmaceuticals, Inc.)|YCBD: Kapitalisasi marang prakiraan pendapatan|PRFX - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan Altamira Therapeutics (CYTO)|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan OPTN|Multiplikator forward rega marang pendapatan PIRS|PROC (procapsgroup.com) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Petros Pharmaceuticals, Inc. (PTPI)|Multiplikator forward rega marang pendapatan Qilian International Holding Group QLI|Rasio rega marang prakiraan pendapatan ACELYRIN, Inc. SLRN|TFFP (TFF Pharmaceuticals, Inc) - Rega mangsa ngarep marang pendapatan
